Novartis' New Heart Failure Drug Cuts Cardiovascular Death Risk By 20%

Novartis AG's (NYSE:NVS) combination heart-failure drug LCZ696 made pulses race Saturday as the company released the final results of its comparative Paradigm-HF clinical trial. The data showed the medication in relation to the ACE-inhibitor enalapril cut the risk of death from cardiovascular causes by 20 percent and from all causes by 16 percent. The pill also reduced hospitalizations due to heart failure by 21 percent.